Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Supramolecular Self-Replicating Antimicrobials

Project description

Introducing supramolecular self-replicating antimicrobials

Antimicrobials are essential to treat and cure disease and infection. However, the high mutation rates of microbes and their capacity to develop resistance pose a threat to the effectiveness of many existing antimicrobials. This calls for the development of new antimicrobial agents with novel mechanisms. The ERC-funded Replicate project aims to design a new family of supramolecular self-replicating antimicrobials as an alternative to widely used single-molecule drugs. Specific metabolic routes of bacteria will transport dormant supramolecular precursors into the bacterial membrane where they will band together to create self-assembling peptide amphiphiles. Once established, the assemblies can catalyse their own synthesis, or self-replicate, thus accelerating production of peptide amphiphiles to increase membrane damage in target pathogens.

Objective

This project aims to address the urgent need for new antimicrobial agents by developing a conceptually new strategy to damage bacterial membranes with supramolecular fibres.

Dormant (non-assembling) precursors will accumulate in the membrane of bacteria for in situ switch-on of self-assembly and membrane lysis. Specific metabolic routes of bacteria, absent in mammalian cells, will be used to transport supramolecular precursors into the membrane of bacteria with full cell specificity. Once in the membrane, precursors will combine to generate self-assembling peptide amphiphiles (PAs).

Importantly, once formed, the supramolecular assemblies can catalyse their own synthesis in bacterial membranes, causing a dramatic acceleration in PA production and antimicrobial fibrillation. This unprecedented antimicrobial design borrows concepts from cooperative self-assembly, supramolecular autocatalysis and rational peptide design, leading to a self-amplified therapeutic action.

This will be the first self-replicating antimicrobial that can make copies of itself to boost membrane damage once activated in target pathogens. Co-assembly of PAs and their precursors will create catalytic microenvironments by templation of reactive building blocks.

Overall, this project will lay down structural and mechanistic determinants for biological membrane interfacing with targeted and self-replicating supramolecular nanomaterials.

In a broader picture, the REPLICATE technology aims to spark a re-conceptualisation of drug design by drawing the attention to supramolecular therapeutics, which may open new exciting opportunities in biomedicine not accessible from traditional single-molecule drugs.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA
Net EU contribution
€ 1 499 496,00
Address
COLEXIO DE SAN XEROME PRAZA DO OBRADOIRO S/N
15782 Santiago De Compostela
Spain
Region
Noroeste Galicia A Coruña
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 499 496,00

Beneficiaries (1)